Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson’s disease

We performed post-mortem studies on two patients with advanced Parkinson’s disease 8 and10 years following AAV2-neurturin (CERE120) gene therapy, the longest post-mortem trophic factor gene therapy cases reported to date. CERE120 was delivered to the putamen bilaterally in one case (10 years post-su...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yaping, Bartus, Raymond T, Manfredsson, Fredric P, Olanow, C Warren, Kordower, Jeffrey H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089653/
https://www.ncbi.nlm.nih.gov/pubmed/32203581
http://dx.doi.org/10.1093/brain/awaa020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089653/
https://www.ncbi.nlm.nih.gov/pubmed/32203581
http://dx.doi.org/10.1093/brain/awaa020

Ejemplares similares